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The purpose of the presented investigations is to design, construct and
establish the characteristic performance of the Jagiellonian Positron Emis-
sion Mammography (J-PEM), being designed for the detection and diag-
nosis of breast cancer. Its construction is based on a novel idea of PET
tomography based on plastic scintillators and wavelength shifter (WLS),
and a new concept of positronium imaging. We have prepared a simulation
program based on Monte Carlo methods for optimizing the geometry and
material of the J-PEM prototype. Here, we present the first results from
the simulations and a brief review of the state of art of breast imaging
modalities and their characteristics motivating our investigation.
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1. Introduction
Breast cancer is the most common cancer and the main cause of death
in females. Breast cancer is the most common cancer and the leading cause
of death in females, and by far the most frequent cancer among women
with an estimated 1.67 million new cancer cases diagnosed in 2012 (25% of
all cancers) [1, 2]. Diagnosis of breast cancer at earlier stages can result
in improved outcomes when followed by timely and appropriate treatment,
which allows for simpler and more cost-effective treatment to reduce both
morbidity and mortality. The main point of making a diagnostic test is to
decrease doctors doubt that a patient has a specific sickness, to the degree
that they can settle on the board choices [3]. There is basic estimation of
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interpretation performance of screening tests which are based on sensitiv-
ity, specificity, positive predictive value, and cancer stage at diagnosis [4].
Sensitivity and specificity describe what a test can and cannot tell us, re-
spectively. Both are expected to completely comprehend a tests qualities as
well as its weaknesses.
In more detail, sensitivity is expressed in percentage and defines the
proportion of true positive subjects with the disease in a total group of
subjects with the disease (True Positive/(True Positive+False Negative)).
Sensitivity is defined as the probability of getting a positive test result in
subjects with the disease. Hence, it relates to the potential of a test to
recognise subjects with the disease [5].
Specificity is the number of true negative cases divided by the sum of
true negatives and false positives. In other words, specificity represents
the probability of a negative test result in a subject without the disease.
Therefore, we can postulate that specificity relates to the aspect of diagnostic
accuracy that describes the test ability to recognise subjects without the
disease, i.e. to exclude the condition of interest.
The positive predictive value is the likelihood of having invasive cancer if
one is recalled for assessment (true positive cases divided by the sum of the
true positive and false positive cases). A test that is highly sensitive will flag
almost everyone who has the disease and not generate many false-negative
results, and a high-specificity test will effectively preclude nearly everyone
who does not have the disease and will not create many false-positive re-
sults [5]. Sensitivity and specificity are rather small for all the conventional
methods used for detection of breast cancer which leads to the problem that,
for women between ages 50 and 69 who go for the breast check-up, around
10% of women are ill but not treated. Between 20 and 25% of women, de-
pending on the detection method, are wrongly diagnosed to have a cancer
which leads to unnecessary biopsies [6, 7]. Because of the small dimensions
of these lesions, a few millimeters in diameter, a detector system for such an
application must have high sensitivity and good spatial resolution. Nowa-
days in present imaging modalities, sensitivity is compromised in the case of
dense breasts, where it is difficult to distinguish between the tumor and the
normal tissues. Therefore, new diagnosis processes and systems for breast
cancer are the subject of much research effort. One such a research line relies
on the use of Positron Emission based technology. This is the case of the
development of the J-PEM scanner, based on positron emission mammog-
raphy (PEM) system, which aims at the detection of tumors with diameters
down to 1 mm. The requirements for high sensitivity and good spatial
resolution can be fulfilled by J-PEM which combines wavelength shifters
along with plastic scintillators, compact photo-detectors, large angular ac-
ceptance, depth-of-interaction (DOI) measurement capability and efficient
data acquisition systems.
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In this paper, the J-PEM prototype for positron emission mammography
is presented. Our focus is given to the system design and preliminary results
from simulations for the validation of the detection techniques and system
performance. In Section 2, we have described possible imaging modalities
with the given sensitivity and specificity. Nevertheless, neither sensitivity
nor specificity are influenced by the disease prevalence, meaning that results
from one study could easily be transferred to some other setting with a
different prevalence of the disease in the population. Nonetheless, sensitivity
and specificity can vary greatly depending on the spectrum of the disease in
the studied group [8]. Section 3 details the concept behind J-PEM and the
possibilities of positronium imaging [9, 10]. Section 4 presents preliminary
results using Monte Carlo simulation, performed using the GATE toolkit.
2. Screening test
The goal of screening asymptomatic women is to find breast cancer in
its earliest stages when treatment has the highest chance for survival. For
diagnosis and characterization of primary breast lesions, anatomical imaging
such as mammography is the most common screening test for breast cancer,
which is basically an X-ray picture of the breast. Examples of mammography
images for a 67 year old patient are shown in Fig. 1. Mammography may find
tumors that are too small to feel. It may also find ductal carcinoma in situ
Fig. 1. Example of mammography images. Patient 67 y/o. Left: CC (cranio-
caudal) views; right: MLO (mediolateral) views of both breasts. In the right breast,
upper outer quadrant, approx. 6 cm from the nipple cluster of microcalcifications
is visible (50 × 70 mm2). In the background of these microcalcifications well-
circumscribed, a dense area (diameter 20 mm) is present. BI-RADS cat. V. The
image is provided by the Maria Skłodowska-Curie Memorial Institute of Oncology
in Kraków, Poland.
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(DCIS) [11]. Mammography is more averse to discover breast tumors in
women with dense breast tissue. Since both tumors and dense breast tissue
show white on a mammogram, it is hard to find a tumor when there is
a dense breast tissue. The mammography sensitivity varies in the range
depending on the age of the examined group and number. This range for
sensitivity varies from 80% to 96% and in the case of specificity, it is in the
range of 15 to 51.8% [12].
However, there is also a novel technique developed in the last few years
based on the mammography methodology: contrast-enhanced spectral mam-
mography (CESM). This method, like MRI, is based on imaging of tumor
neoangiogenesis by the use of a contrast agent [13, 14]. CESM uses a chelated
iodine-base X-ray contrast agent, while MRI uses a chelated gadolinium-
based paramagnetic agent [15, 16]. Due to the high sensitivity of CESM
(similar to sensitivity of MRI), this technique may be in some cases com-
parable with MRI. CESM, like other diagnostic methods, has some limita-
tions. Benign lesions enhance on CESM, just as they do on MRI. That is,
there is no possibility to generate a time-enhancement curve, comparable to
that in breast MRI [12, 17]. Just as with mammography, CSEM sensitivity
and specificity also varies depending on the age of the examined group and
number. Sensitivity and specificity varies from 92.7% to 100% and 41% to
69.7%, respectively [12]. Exemplary CSEM images for CC and MLO views
are shown in Fig. 2.
Fig. 2. Example of CESM images of the same 67 y/o patient as in Fig. 1, left:
CC (cranio-caudal) views; right: MLO (mediolateral) views of both breasts. Right
breast, upper outer quadrant, pathological contrast enhancement area is visible
(dimensions 110×75 mm2). BI-RADS category V. The image was provided by the
Maria Skłodowska-Curie Memorial Institute of Oncology in Kraków, Poland.
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Digital breast tomosynthesis (DBT) is a promising new technology for
acquiring and displaying three-dimensional mammograms [18]. Due to its
improved ability to differentiate true breast lesion or summation of normal
breast structures. An example image of tomosynthesis is shown in Fig. 3, for
the different planes, it has improved characterization of masses. Tomosyn-
thesis is being increasingly used in the diagnostic setting to evaluate masses,
asymmetries, and architectural distortion. Tomosynthesis can be done in
full or spot compression views as needed [19]. The sensitivity and specificity
of DBT ranged from 74.2% to 86.9% and 97.0% to 97.5%, respectively [20].
Fig. 3. Example of tomosynthesis planes of 29 y/o patient — in the planes, there
are numerous well-limited shadows architectural distortion and microcalcifications
on histopathology — papillary carcinoma in the right breast. Breast thickening
observed for 3 years. The right breast ultrasound, visualized numerous solid and
fluid lesions. The image was provided by the Maria Skłodowska-Curie Memorial
Institute of Oncology in Kraków, Poland.
Ultrasound is well-accepted as the most useful adjunct to mammography
for the diagnosis of breast abnormalities. An exemplary ultrasound image of
the right breast of a patient is shown in Fig. 4. Ultrasound is most often used
to assess palpable masses and nonpalpable masses that have been detected
during screening mammography [21, 22]. Ultrasound may demonstrate ma-
lignancies and other masses that are not visible mammographically [23].
Ultrasound had an overall pooled sensitivity and specificity of 80.1% and
88.4%, respectively [12].
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Fig. 4. Example image of breast ultrasound (the same patient as in Fig. 1). Right
breast, outer upper quadrant, 7 cm from the nipple not well-defined hypoechogenic
area (dimensions: 24 × 20 mm2) is visible. BI-RADS category IV c. The image
was provided by the Maria Skłodowska-Curie Memorial Institute of Oncology in
Kraków, Poland.
Molecular breast imaging (MBI) is a nuclear medicine technique that
uses dedicated gamma cameras to image the physiologic uptake of a radio-
pharmaceutical, typically 99mTc-sestamibi, in the breast. MBI is capable
of detecting mammographically occult cancers, particularly in women with
dense breasts [24, 25]. MBI has an overall sensitivity of 90%, with a sensi-
tivity of 82% for lesions less than 10 mm in size [26].
Magnetic resonance imaging (MRI) has been used as an adjunctive screen-
ing tool, mainly for women who may be at increased risk for the development
of breast cancer. Example images of MRI are shown in Fig. 5 with T1 con-
trast enhancement. MRI for screening has not been very popular in women
with average risk due to concerns about the low specificity leading to ad-
ditional biopsies, time and cost of technology [27]. Breast MRI sensitivity
values reported in high risk screening studies range from 93% to 99%. De-
spite its high sensitivity, breast MRI has been reported to have variable
specificity, ranging from 50% to 85% [28]. These numbers of sensitivity and
specificity depend on the type of tumor, size of tumor, age of patient, and
where it is localised.
Then, there is positron emission mammography which is a new technol-
ogy that is designed for the imaging of specific small body parts. To achieve
high resolution, it uses short-lived positron-emitting isotopes to generate
images of cancer within the breast [29]. It has better specificity as com-
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Fig. 5. Example images of breast MRI (MIP, subtraction T1 contrast enhanced
image, T1 contrast image with fat saturation). The image is provided by the
Maria Skłodowska-Curie Memorial Institute of Oncology in Kraków, Poland.
pared to MRI, which confines the unneeded biopsies. The potential basis for
the improved sensitivity of PEM is enhanced spatial resolution [30], which
enables detection of small lesions. This is our motivation for developing J-
PEM. PEM has a higher imaging sensitivity in small tumors < 2 cm. Even
in very small tumors < 1 cm, the imaging sensitivity was acceptable at 60–
70% [30]. The standard sensitivity and specificity of PEM is 80% and 100%,
respectively [31].
3. Concept of J-PEM
The J-PEM is a prototype intended to evaluate PET technology in the
diagnosis of malign neoplasm in the breast and of ganglion loco-regional in-
vasion. It is based on plastic scintillators and utilizes the same technology as
the Jagiellonian Positron Emmision Tomograph, J-PET [32]. It is optimized
for the detection of photons from electron–positron annihilation [33, 34].
Such photons, having an energy of 511 keV, interact with electrons in plastic
scintillators predominantly via the Compton effect. J-PEM uses a dedicated
instrument for breast cancer detection that is equipped with two parallel
photon detectors in a configuration similar to mammography compressors.
The detector system consists of two modules of plastic scintillators, with
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each module built from two layers of plastic scintillator and the wavelength
shifters [35, 36] placed orthogonally between them, as shown in Fig. 6. Each
scintillator bar is attached at both ends to Silicon Photomultipliers for the
signal readout [33]. The combined use of plastic scintillators, which have
superior timing properties, with the WLS strips can provide an affordable
and precise scanner with significant improvement in spatial resolution and
efficiency for the detection of breast cancer. Plastic scintillators are charac-
terized by short light decay time which is of the order of 1.5 ns [33]. This
enables one to achieve high time resolution. In J-PET, a solution for the
position of the interaction point of photons is based on the measurement of
the time of the signals arrival to the ends of the long scintillator strips. So
far, a resolution of about 10 mm was achieved [36]. In order to achieve a high
resolution, we propose to register scintillation light escaping the scintillator
bar through a side wall using an array of WLS. It has been already proven
that one can reach to position resolution of 5 mm for the coordinate along
the scintillator bar.
Fig. 6. (Colour on-line) Top figure: Geometry scheme of J-PEM used in GATE sim-
ulation. Here, grey/blue colour represents plastic scintillators and light grey/green
colour represents wavelength shifters. Dimension of plastic scintillators and WLS
were 6 × 24 × 500 mm3 and 3 × 10 × 100 mm3, respectively. Space between the
modules is 33.88 cm. Bottom left and right are the Y –Z and X–Y plane views of
the given geometry for single module.
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J-PET is capable of performing simultaneous imaging of the density
distribution of annihilation points as well as positron annihilation lifetime
spectroscopy [9, 37]. The positronium imaging technique has successfully
distinguished cancer from healthy tissue by in vitro probing of human tissues
or in the in vitro organoid (3D cell culture) systems [38]. Study of positron-
ium decay can provide new data in medical diagnosis as the mean lifetime of
positronium depends on the size of free volume between atoms, whereas its
formation probability depends on the concentration of voids [39]. In the free
space between atoms, positronium decays as it does in vacuum [9]. How-
ever, within molecules, there are additional annihilation possibilities and the
mean lifetime of ortho-positronium decreases significantly compared with the
lifetime in vacuum, from 142 ns to a few nanoseconds [40]. The reconstruc-
tion of positronium lifetime requires determination of times of its creation
and annihilation. These can be achieved when applying radiopharmaceu-
ticals labeled with isotopes such as scandium-44, which after emission of
the positron changes into a daughter nucleus in an excited state [10]. A
technique that combines PALS and PET in clinical use must enable deter-
mination of positronium parameters in a position-sensitive manner, and it
needs to be scaled to work for living organisms. Recently, a first possible so-
lution designed for the size of a human body was proposed. In vitro studies
comparing the positronium properties in cancerous and healthy tissues sug-
gest that the ortho-positronium mean lifetime is correlated with the grade
of development of metabolic disorders in cancer cells [39, 40]. Combining
the information about metabolism with information about the structure of
tissue will improve specificity and sensitivity, thus increasing the accuracy
of the examination.
4. Monte Carlo simulation
In order to quantify the J-PEM geometry, we have performed Monte
Carlo simulations. The simulations were performed using the GATE pack-
age. GATE (Geant4 Application for Tomographic Emission) is a Monte Carlo
simulation platform developed by the Open-GATE Collaboration [41] based
on Geant4 software. It is dedicated to numerical simulations in medical
imaging and radiotherapy. It utilizes an easy macro-mechanism to config-
ure the experimental settings for computed tomography, single-photon emis-
sion computed tomography, positron-emission tomography as well as optical
imaging (bioluminescence and fluorescence) or radiotherapy. In the simula-
tions, the full geometry of the J-PEM detector and the composition of the
detector material were taken into account. The interactions of photons in
the scintillators were simulated by GATE. In the simulations, we assumed
that annihilation source is placed in the center of the detector and that
the back-to-back photons (each with energy of 511 keV) from the Ps → 2γ
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annihilation are isotropically emitted. Energy deposition inside the plastic
scintillator is shown in Fig. 7. According to the performed simulation, we
are able to register 4.33% of generated back-to-back events. After adding
the condition that both photons deposited at least 200 keV energy, the frac-
tion of register annihilation drops to 0.8%. Such a condition is needed for
the suppression of the scatter fraction [42]. We found that there was 11.3%
primary back-to-back registered events where at least one photon scattered
in WLS. The J-PEM simulation will be used to evaluate the performance of
various detector configurations and options. Sensitivity estimations, study
of the depth-of-interaction measurement technique and estimation of the
background rates are some examples of basic information to be obtained
from the simulation and that is needed to finalize the detector concept. Fi-
nally, simulated events will be also used as an input to the reconstruction
software.
Fig. 7. Top left: the number of interactions per scintillator ID for back-to-back
photons. Top right: the number of interactions per scintillator ID for back to
back photons with condition that both photons deposited at least 200 keV energy.
Scintillators in the inner and outer layer of upper module are numbered from 1 to
13 and 14 to 26, respectively, while WLS in the upper module are numbered from
27 to 67. Scintillators in the inner and outer layer of down module are numbered
from 68 to 81 and 82 to 94, respectively. WLS numbering for down module are
from 95 to 135. Figure in bottom shows energy deposition of primary photons.
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5. Conclusion
In this paper, we have investigated the design, construction and es-
tablishment of the characteristic performance of the Jagiellonian Positron
Emission Mammography (J-PEM) for the detection and diagnosis of breast
cancer. Its construction is based on a novel idea of PET based on plastic
scintillators and wavelength shifter (WLS), and a new concept of positro-
nium imaging. We have prepared a simulation program based on Monte
Carlo method using GATE toolkit, for optimizing the geometry and material
for the J-PEM prototype. We have also presented the first results from the
simulations and a brief review of the state of art of breast imaging modali-
ties and their characteristics motivating our investigation. Results from the
simulations are showing that the amount of registered back-to-back events
are comparable to those of conventional secondary screening methods for
breast cancer [43], thus making J-PEM a viable tool in early detection of
cancer.
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